Literature DB >> 26386855

New, Expensive Treatments for Chronic Hepatitis C: Insuring Good Outcomes?

Jeremy D Goldhaber-Fiebert1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26386855     DOI: 10.1007/s10620-015-3818-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

1.  Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage.

Authors:  Maria Stepanova; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

2.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Authors:  David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

3.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

4.  Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.

Authors:  Shan Liu; Daena Watcha; Mark Holodniy; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2014-10-21       Impact factor: 25.391

5.  Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans.

Authors:  R Gidwani; P G Barnett; J D Goldhaber-Fiebert; S M Asch; J Lo; S K Dally; D K Owens
Journal:  J Viral Hepat       Date:  2014-11-24       Impact factor: 3.517

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.